Open an account

Replimune Group

REPL · NASDAQ

$11.42+$0.37 (+3.35%)TodayMarket closed ·
Prev close $11.05

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 479 full-time employees. The company went IPO on 2018-07-20. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. The company has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.

Employees
479
Headquarters
Woburn, Massachusetts
Listed
Jul 20, 2018
Sector
Health Care
Industry
Biotechnology
Website
replimune.com

REPL key statistics

Market cap
1.08B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.01M
Volume
1.39M
Open price
$11.04
High today
$11.69
Low today
$11.00
52 Week high
$16.33
52 Week low
$1.50

Replimune Group (REPL) at a glance

Replimune Group (REPL) last traded at $11.42, with a market cap of 1.08B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $11.00 and $11.69. The current price is 3.9% above the day's low and 2.3% below its high.

Volume so far is 1.39M shares, below the average of 2.01M shares a day.

Over the past year Replimune Group has ranged from $1.50 to $16.33, and now sits 67% of the way up that range.

Replimune Group met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.72 per share against an estimate of -$0.7324.

The average analyst price target is $19.55, 71.2% above the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

63%of 8 analyst ratings say Buy
  • Buy62.5%
  • Hold25.0%
  • Sell12.5%
Price target · 9 analystsAvg $19.55
Low
$14.14
Now
$11.42
High
$25.20

REPL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 6.6% on average.

  1. Q4 FY24: reported -$0.82 per share against an estimate of -$0.8084
  2. Q1 FY25: reported -$0.78 per share against an estimate of -$0.8683
  3. Q2 FY25: reported -$0.68 per share against an estimate of -$0.781
  4. Q3 FY25: reported -$0.79 per share against an estimate of -$0.6875
  5. Q4 FY25: reported -$0.82 per share against an estimate of -$0.7677
  6. Q1 FY26: reported -$0.76 per share against an estimate of -$0.7271
  7. Q1 FY27: reported -$0.72 per share against an estimate of -$0.7324
  8. Q2 FY26: reported -$0.72 per share against an estimate of -$0.7324

REPL news

  • Press releasePRNewswire

    SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

  • Press releasePRNewswire

    REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky

  • Press releaseGlobe Newswire

    REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

  • Press releaseNewsfile

    Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

  • Press releasePRNewswire

    REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026

  • Press releasePRNewswire

    REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm

  • Press releaseGlobe Newswire

    Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors

Similar companies

Companies in the same industry as Replimune Group

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.